Acasti Pharma Inc (NASDAQ:ACST) has been given a consensus rating of “Buy” by the seven analysts that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $7.25.

A number of research firms recently issued reports on ACST. Zacks Investment Research downgraded shares of Acasti Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. HC Wainwright restated a “buy” rating on shares of Acasti Pharma in a report on Thursday, August 15th. Aegis began coverage on shares of Acasti Pharma in a report on Tuesday, July 9th. They set a “buy” rating for the company. Oppenheimer began coverage on shares of Acasti Pharma in a report on Thursday, July 18th. They set an “outperform” rating and a $7.00 price objective for the company. Finally, B. Riley began coverage on shares of Acasti Pharma in a report on Thursday, August 29th. They set a “buy” rating and a $7.75 price objective for the company.

Shares of ACST stock traded down $0.01 on Friday, hitting $2.14. The stock had a trading volume of 313,417 shares, compared to its average volume of 1,033,509. The business has a 50 day moving average of $2.08 and a 200 day moving average of $1.31. The stock has a market cap of $181.96 million, a price-to-earnings ratio of -3.01 and a beta of 1.35. Acasti Pharma has a 12-month low of $0.52 and a 12-month high of $2.95.

Acasti Pharma (NASDAQ:ACST) last posted its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. As a group, equities analysts forecast that Acasti Pharma will post -0.31 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of ACST. Geode Capital Management LLC purchased a new stake in Acasti Pharma during the fourth quarter worth about $40,000. Morgan Stanley boosted its position in Acasti Pharma by 20.6% during the second quarter. Morgan Stanley now owns 45,687 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 7,789 shares during the period. Finally, Bank of Montreal Can boosted its position in Acasti Pharma by 2.0% during the second quarter. Bank of Montreal Can now owns 253,287 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 5,000 shares during the period. Institutional investors and hedge funds own 2.96% of the company’s stock.

Acasti Pharma Company Profile

Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.

Recommended Story: Golden Cross

Analyst Recommendations for Acasti Pharma (NASDAQ:ACST)

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.